Skip to content

Contact +44 (0) 20 7060 7474 email us

Orthopaedic

Osteoporosis Therapeutics

A Global Market Perspective

Publication Date November 2009
Publisher BizAcumen
Product Type Report
Pages 166
ISBN Number not applicable
Product Code BIZ00156

Price

£1,995.00
approximately: $2,998 | €2,187

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Osteoporosis, the most common type of metabolic bone diseases, is an implacable epidemic growing rapidly in regions of North America, Europe, and Japan. Afflicting millions of people across the world, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Major therapeutic classes currently available include bisphosphonates, Estrogen Replacement Therapy (ERT) drugs, calcitonins and Selective Estrogen Receptor Modulators (SERMs). Parathyroid Hormone (PTH)-based drugs comprise the most recent genre of therapeutics with new bone-forming potential. As osteoporosis is asymptomic, several cases of osteoporosis are detected only after experiencing a fracture.

These and other market data and trends are presented in "Osteoporosis Therapeutics: A Global Market Perspective" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Contents

  • 1.Methodology
    • Study Reliability and Reporting Limitations
    • Disclaimers
    • Quantitative Techniques & Reporting Level
  • 2.Outlook
  • 3.Industry Overview
    • Osteoporosis Therapeutics: An Evolutionary Scan
    • ""a Sketch of The Present Industry Scenario""
    • Facts & Figures: The Osteoporosis Primacy
    • Snapshots
    • Factors Influencing Demand
    • Competitive Landscape
    • Market Trends and Issues
    • Can New Treatments Beat The Gold Standard?
    • Oral Calcitonin Likely to Emerge as Wonder Drug
    • New Bisphosphonates Challenge Established Brands
    • Side Effects of Hrt Fuel Natural Alternatives Sales
    • Bone Formation Drugs Augur New Prospects
    • Estrogen Replacement Therapy: Will Dosing Make A Difference?
    • Is Prevention Always Better than Cure?
    • Peptide-Based Osteoporosis Therapy Gaining Ground
    • Polymorphism- A Potent Diagnostic Marker
    • Bisphosphonates - The Other Side
    • Efficacy of Evista under The Scanner
  • 4.Major Therapeutic Classes: A Global Perspective
    • Ert Drugs
    • Ups and Downs in The Ert Market
    • Bisphosphonates
    • The Leading Therapeutic Market
    • Serms (Selective Estrogen Receptor Modulators)
    • Market Overview
    • Calcitonins
    • Market Overview
  • 5.Product Facts
    • Bisphosphonates
    • Hormone Replacement Therapy/ Estrogen Replacement Therapy
    • Estrogens
    • Estrogens/Progesterones
    • Calcitonins
    • Selective Estrogen Receptor Modulators (Serms)
    • Other Therapeutics
  • 6.Major Clinical Trials/Findings
  • 7.Corporate Developments
    • Schering-Plough Acquires Organon Biosciences
    • Faes Farma Signs Marketing Agreement with Roche and Glaxosmithkline
    • Alethia and Emerillon Collaborate on Osteoporosis Therapies
    • Ipsen Enters into Co-Marketing Agreement with Msd
    • Unigene Enters into Agreement with Novartis
    • Pharming Group Granted Subsidies to Develop Osteoporosis Drugs
    • Procter & Gamble Terminates Nasal Spray Collaboration with Nastech- Pharmaceutical
    • Gsk & Nps Collaborate for Phase Ii Clinical Study of Calcilytics
    • Radius Initiates Phase Ii Trials for Ba058
    • Novartis and Nordic Initiate Phase Iii Clinical Trial of Oral Salmon Calcitonin
    • Medivir Initiates First Human Trials for Miv-701
    • P&g Receives Fda Approval for New Dosage of Actonel
    • Takeda Introduces Benet for Osteoporosis Treatment
    • Labtec Obtains Approval to Market Hormone Replacement Patch in Europe
    • Wyeth Obtains Conditional Approval for Osteoporosis Drug from Fda
    • Merck's New Dosage of Fosamax plus D Gains Fda Approval
    • Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug
  • 8.Major Players
    • Eli Lilly and Company (US)
    • F.Hoffmann-La Roche Ltd (Switzerland)
    • Merck & Co., Inc. (US)
    • Novartis Ag (Switzerland)
    • Novo Nordisk A/S (Denmark)
    • Organon
    • Procter & Gamble Pharmaceuticals Inc. (US)
    • Sanofi-Aventis Sa (France)
    • Servier Sa (France)
    • Solvay Pharmaceuticals Inc. (US)
    • Unigene Laboratories, Inc. (US)
    • Wyeth (US)
  • 9.Global Market Analytics
  • 10.The United States
    • Industry Overview
    • Osteoporosis in The US: An Insight
    • Osteoporosis - An Underserved Market?
    • Osteoporosis Prescription Market
    • Competitive Scenario
    • Competitive Review by Segment
    • Bisphosphonates
    • Serms
    • Calcitonins
    • Pth Therapy
  • 11.Japan
  • 12.Europe
    • A.France
    • B.Germany
    • C.The United Kingdom
    • D.Italy
    • E.Spain
    • F.Rest of Europe
  • 13.Rest of World
    • Prevalence of Osteoporosis in Various Region-at A Glance
    • Korea
    • China
  • Exhibits
    • Table 1: Prevalence of Osteoporosis and Osteopenia in Major Markets Worldwide - 2008 &
    • Table 2: Percentage Breakdown of Leading Players in The Global Osteoporosis Market -
    • Table 3: Leading Osteoporosis Drugs Worldwide by Dollar Sales -
    • Table 4: Leading Osteoporosis Therapies and Its Cost per Day
    • Table 5: Global Osteoporosis Therapeutics Market by Region for The Period 2007-2015 (Sales in US$ Million)
    • Table 6: Percentage Breakdown of Global Osteoporosis Therapeutics Market by Region for The Years 2008 &
    • Table 7: Global Bisphosphonates Market by Region for The Period 2007-2015 (Sales in US$ Million)
    • Table 8: Percentage Breakdown of Global Bisphosphonates Market by Region for The Years 2008 &
    • Table 9: Global Ert Drugs Market by Region for The Period 2007-2015 (Sales in US$ Million)
    • Table 10: Percentage Breakdown of Global Ert Drugs Market by Region for The Years 2008 &
    • Table 11: Global Serm Market by Region for The Period 2007-2015 (Sales in US$ Million)
    • Table 12: Percentage Breakdown of Global Serm Market by Region for The Years 2008 &
    • Table 13: Global Calcitonins Market by Region for The Period 2007-2015 (Sales in US$ Million)
    • Table 14: Percentage Breakdown of Global Calcitonins Market by Region for The Years 2008 &
    • Table 15: Market Shares of Leading Osteoporosis Drugs in The US
    • Table 16: Market Shares of Leading Players in The US Osteoporosis Market -
    • Table 17: Market Shares of Leading Players in The US Bisphosphonates Market -
    • Table 18: Osteoporosis Therapeutics Market by Product Group in The US: 2007-2015 (Sales in US$ Million)
    • Table 19: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in The US for The Years 2008 &
    • Table 20: Osteoporosis Therapeutics Market by Product Group in Japan: 2007-2015 (Sales in US$ Million)
    • Table 21: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Japan for The Years 2008 &
    • Table 22: Market Shares of Leading Players in The European Market for Osteoporosis Therapeutics (2005)
    • Table 23: Osteoporosis Therapeutics Market by Region in Europe: 2007-2015 (Sales in US$ Million)
    • Table 24: Percentage Breakdown of Osteoporosis Therapeutics Market by Region in Europe for The Years 2008 &
    • Table 25: Osteoporosis Therapeutics Market by Product Group in Europe: 2007-2015 (Sales in US$ Million)
    • Table 26: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Europe for The Years 2008 &
    • Table 27: Osteoporosis Therapeutics Market by Product Group in France: 2007-2015 (Sales in US$ Million)
    • Table 28: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in France for The Years 2008 &
    • Table 29: Osteoporosis Therapeutics Market by Product Group in Germany: 2007-2015 (Sales in US$ Million)
    • Table 30: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Germany for The Years 2008 &
    • Table 31: Osteoporosis Therapeutics Market by Product Group in The UK: 2007-2015 (Sales in US$ Million)
    • Table 32: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in The UK for The Years 2008 &
    • Table 33: Osteoporosis Therapeutics Market by Product Group in Italy: 2007-2015 (Sales in US$ Million)
    • Table 34: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Italy for The Years 2008 &
    • Table 35: Osteoporosis Therapeutics Market by Product Group in Spain: 2007-2015 (Sales in US$ Million)
    • Table 36: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Spain for The Years 2008 &
    • Table 37: Osteoporosis Therapeutics Market by Product Group in Rest of Europe: 2007-2015 (Sales in US$ Million)
    • Table 38: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Rest of Europe for The Years 2008 &
    • Table 39: Percentage Breakdown of Leading Brands in The Korean Osteoporosis Therapeutics Market -
    • Table 40: Osteoporosis Therapeutics Market by Product Group in Rest of World: 2007-2015 (Sales in US$ Million)
    • Table 41: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Rest of World for The Years 2008 & 2012companies Profiled